Frey Gary, Rits-Volloch Sophia, Zhang X-Q, Schooley Robert T, Chen Bing, Harrison Stephen C
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA.
Proc Natl Acad Sci U S A. 2006 Sep 19;103(38):13938-43. doi: 10.1073/pnas.0601036103. Epub 2006 Sep 8.
HIV-1 enters cells by membrane fusion, mediated by the trimeric viral envelope glycoprotein gp160, which is processed by a single proteolytic cleavage into stably associated gp120 and gp41. The gp120/gp41 trimer can be triggered to undergo an irreversible conformational change. Using a protein-based assay designed to mimic the gp41 conformational change, we screened for small molecules that prevent the formation of postfusion gp41. Several compounds were identified. One set of structurally related molecules inhibited formation of a postfusion-like assembly with an IC50 of approximately 5 microM. The compounds also inhibited envelope-mediated membrane fusion in both cell-cell fusion and viral infectivity assays. Thus, our screen identifies effective fusion inhibitors. Tested against a panel of envelope proteins from primary HIV-1 isolates, the compounds inhibited fusion across a broad range of clades, including both M and T tropic strains. They bind in a highly conserved, hydrophobic pocket on the inner core of the gp41 trimer, a region previously identified as a potential inhibitor site.
HIV-1通过三聚体病毒包膜糖蛋白gp160介导的膜融合进入细胞,gp160经单次蛋白水解切割后加工成稳定结合的gp120和gp41。gp120/gp41三聚体可被触发发生不可逆的构象变化。我们使用一种基于蛋白质的检测方法来模拟gp41的构象变化,筛选能够阻止融合后gp41形成的小分子。鉴定出了几种化合物。一组结构相关的分子抑制了类似融合后组装体的形成,IC50约为5微摩尔。这些化合物在细胞-细胞融合和病毒感染性检测中也抑制了包膜介导的膜融合。因此,我们的筛选鉴定出了有效的融合抑制剂。在针对一组来自原发性HIV-1分离株的包膜蛋白进行测试时,这些化合物抑制了广泛谱系的融合,包括M和T嗜性毒株。它们结合在gp41三聚体内核上一个高度保守的疏水口袋中,该区域先前被确定为一个潜在的抑制剂位点。